Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;2(2):167-76.
doi: 10.4103/0974-777X.62887.

Drug resistance in leishmaniasis

Jaya Chakravarty  1 , Shyam Sundar
Affiliations

Drug resistance in leishmaniasis

Jaya Chakravarty et al. J Glob Infect Dis. 2010 May.

Abstract

The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60 years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb(v)). Widespread misuse has led to the emergence of Sb(v) resistance in the hyperendemic areas of North Bihar. Other antileishmanials could also face the same fate, especially in the anthroponotic cycle. The HIV/ visceral leishmaniasis (VL) coinfected patients are another potential source for the emergence of drug resistance. At present no molecular markers of resistance are available and the only reliable method for monitoring resistance of isolates is the technically demanding in vitro amastigote-macrophage model. As the armametrium of drugs for leishmaniasis is limited, it is important that effective monitoring of drug use and response should be done to prevent the spread of resistance. Regimens of simultaneous or sequential combinations should be seriously considered to limit the emergence of resistance.

Keywords: Antimony; Leishmaniasis; Resistance.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat Q. 1992;45:267–75. - PubMed
    1. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India. 1999;12:62–8. - PubMed
    1. Richens J. Genital manifestations of tropical diseases. Sex Transm Infect. 2004;80:12–7. - PMC - PubMed
    1. Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin. 1995;13:505–23. - PubMed
    1. Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10:298–319. - PMC - PubMed